Although some BRAF mutations occur beyond the V600 hotspot, representing 22% of all BRAF mutations in CRC, they do not have the same biological, clinical, and therapeutic consequences as the V600E mutation [44]. This evidence concerns the gene BRAF and colorectal carcinoma.